Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Laboratories Inc.

Latest From Abbott Laboratories Inc.

Diabetes, Mitral Repair And Diagnostics Drive Big Quarter For Abbott

Abbott Laboratories’ medical device businesses grew 10.6% year over year in the third quarter of 2019 while its diagnostics business grew 6.6%, helping the company grow 7.6% overall, the company reported on 16 October.

Commercial Sales & Earnings

Abbott Sees Little Impact From Chinese Tenders

Competitive procurement practices for off-patent molecules in China are not affecting Abbott adversely because its local Established Pharmaceuticals portfolio is focused on niche, hard-to-make branded generics.

China Business Strategies

Abbott Inks Partnership With Tandem Diabetes Care

Abbott signed a deal with Tandem Diabetes Care to develop diabetes solutions to combine Abbott's glucose-sensing technology with Tandem's insulin delivery systems.

Diabetic Care Commercial

Reata Friedreich's Ataxia Drug Shows Late-Stage MOXIe

Analysts have been surprised by positive pivotal data for omaveloxolone, one of Reata's Nrf2 activators – along with bardoxolone – which the company is buying back from AbbVie for $330m.
Rare Diseases Clinical Trials
See All

Company Information